Side-by-side · Research reference

PEG-MGFvsSurvodutide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED2/69 cited

BPhase 3HUMAN-REVIEWED25/54 cited

PEG-MGF

IGF-1Ec Splice Variant · PEGylated

~2 hrHalf-life (PEG)

~7 minNative MGF t½

IGF-1EcSplice variant

SQ · Research Protocol

Survodutide

GLP-1/Glucagon Dual Agonist · Phase 3

Once weeklyFrequency

Phase 3Development stageRubino 2026

GLP-1/GCGRDual targetZimmermann 2026

SQ · Once Weekly

01Mechanism of Action

Parameter

PEG-MGF

Survodutide

Primary target

IGF-1 receptor on muscle satellite cells and myocytes

GLP-1 receptor and glucagon receptor (GCGR)Yathindra 2026 Zimmermann 2026

Pathway

IGF-1R → PI3K/Akt → mTOR activation → Satellite cell proliferation & myoblast fusion

Central: CVOs → hypothalamic appetite regulation. Peripheral: GLP-1R → incretin effect; GCGR → hepatic lipid metabolism, energy expenditureZimmermann 2026 Long 2026

Downstream effect

Satellite cell activation, muscle fiber repair, localized hypertrophy signaling

Decreased energy intake, increased energy expenditure, improved glucose homeostasis, hepatic fat reductionZimmermann 2026 Yathindra 2026

Feedback intact?

Partially bypassed — does not require hepatic IGF-1 synthesis

—

Origin

IGF-1Ec splice variant (exon 4–6) conjugated to polyethylene glycol for extended circulation

—

Antibody development

Unknown — no long-term human immunogenicity data

—

02Dosage Protocols

Parameter

PEG-MGF

Survodutide

Research dose range

100–200 mcg

Extrapolated from animal models; no validated human protocols.

—

Frequency

Post-training or daily

Timing to match endogenous MGF pulse post-exercise.

Once weekly

Half-life

~2 hours (PEGylated)

Native MGF: ~7 min; PEGylation extends circulation.

—

Evidence basis

Animal / mechanistic

Phase 2 RCT (obesity) · Phase 3 ongoing

Reconstitution

Sterile bacteriostatic water

Lyophilized form; store reconstituted at 2–8 °C.

—

PEG molecular weight

Typically 5–30 kDa

Higher MW = longer t½, greater steric hindrance.

—

Timing

Within 30–60 min post-training

Aligns with endogenous MGF window.

—

Standard dose

—

Not yet disclosed (Phase 3 ongoing)

SYNCHRONIZE Phase 3 program underway.Rubino 2026

Route

—

SubcutaneousYathindra 2026

Phase 2 findings

—

Significant weight loss and metabolic marker improvementYathindra 2026

MASH indication

—

Under investigation for MASH-cirrhosisPatil 2026 Andonie 2026

03Metabolic / Fat Loss Evidence

Parameter

PEG-MGF

Survodutide

Primary target

Muscle tissue (satellite cells, myocytes) — not adipose-specific

—

Indirect metabolic effect

IGF-1 signaling may modulate insulin sensitivity and lipid metabolismRen 2015

Mechanism distinct from direct lipolytic peptides.

—

Body composition

Lean mass preservation / hypertrophy focus

—

Fat loss evidence

No direct human or animal RCT data for PEG-MGF-driven fat reduction

—

Primary fat target

—

Total body weight, visceral adipose tissue

Weight loss mechanism

—

Dual action: decreased energy intake + increased energy expenditureZimmermann 2026

Phase 2 efficacy

—

Significant weight loss demonstrated

Specific percentage not disclosed in abstracts.

Metabolic markers

—

Improvements in ALT, AST, LDL levels; significant ALT reduction (MD -22.10 vs placebo)Yathindra 2026 Abulehia 2026 Andonie 2026

MRI-PDFF reduction

—

Hepatic fat reduction demonstrated in MASH trialsAndonie 2026

Network meta-analysis

—

Favorable efficacy profile vs other glucagon receptor agonists

Hepatic requirement

—

Hepatic GCGR required for maximal weight loss and metabolic effectsLong 2026

Energy expenditure

—

Increased energy expenditure contributes to weight lossZimmermann 2026

Comparative efficacy

—

Network meta-analysis shows competitive efficacy in GRA class

04Side Effects & Safety

Parameter

PEG-MGF

Survodutide

Injection site reaction

Erythema, induration (common with SQ peptides)

—

Hypoglycemia risk

IGF-1 axis activation can lower blood glucose

—

IGF-1R overstimulation

Theoretical risk of aberrant cell proliferation with chronic supraphysiological exposure

—

Fluid retention

Possible with IGF-1 pathway activation (dose-dependent)

—

PEG accumulation

Chronic high-dose PEGylated proteins may accumulate in tissues; clearance slower in renal impairment

—

Antibody formation

PEGylated proteins can elicit anti-PEG antibodies (neutralizing potential unknown)

—

Cancer risk

IGF-1 axis stimulation contraindicated in active malignancy

—

Human safety data

Absent — no published human trials for PEG-MGF

—

GI symptoms

—

Diarrhea, nausea, fatigue — class effect of GLP-1 agonists

Safety profile

—

Network meta-analysis: comparable safety to other GRAs

Serious adverse events

—

Monitored in Phase 2/3; no unique safety signals reported

Detailed SAE data pending Phase 3 completion.

Injection site reactions

—

Expected with subcutaneous administration

Glucagon-related effects

—

Potential for tachycardia, increased blood pressure — theoretical glucagon effect

Absolute Contraindications

PEG-MGF

·Active malignancy or history of cancer (IGF-1R proliferative signaling)
·Known hypersensitivity to PEGylated compounds
·Pregnancy / lactation (no reproductive toxicity data)

Survodutide

·Personal or family history of medullary thyroid carcinoma (class effect)
·Multiple endocrine neoplasia syndrome type 2

Relative Contraindications

PEG-MGF

·Diabetes (monitor glucose closely)
·Renal impairment (PEG clearance reduced)
·Retinopathy (IGF-1 axis effects on vascular proliferation)

Survodutide

·Severe GI disease (inflammatory bowel disease, gastroparesis)
·History of pancreatitis
·Cardiovascular disease (monitor closely for glucagon effects)

05Administration Protocol

Parameter

PEG-MGF

Survodutide

1. Reconstitution

Add 1–2 mL bacteriostatic water to lyophilized vial. Swirl gently — do not shake. Solution should be clear to slightly opalescent.

Specific reconstitution protocol not yet publicly disclosed. Follow manufacturer instructions upon approval.

2. Injection site

Subcutaneous — abdomen or thigh. Rotate sites to avoid lipodystrophy. Avoid areas with scar tissue or active inflammation.

Subcutaneous — abdomen, thigh, or upper arm. Rotate sites weekly to minimize injection site reactions.

3. Timing

Post-training preferred (within 30–60 min) to align with endogenous MGF expression window. Alternatively, daily morning dose on non-training days.

Once weekly, same day each week. Can be administered at any time of day, with or without meals.

4. Storage

Lyophilized: room temperature, light-protected, desiccated. Reconstituted: refrigerate 2–8 °C, use within 14–21 days.

Store refrigerated (2–8 °C) until use. Do not freeze. Protect from light. Specific reconstituted storage duration pending labeling.

5. Needle

29–31G insulin syringe, 8–12 mm length. Pinch skin fold, insert at 45° angle for subcutaneous delivery.

Subcutaneous injection with appropriate gauge needle (typically 27–31G). Use sterile technique.

06Stack Synergy

PEG-MGF

+ BPC-157

Moderate

View BPC-157 →

BPC-157 promotes angiogenesis and tendon/ligament repair via VEGF and growth factor modulation, while PEG-MGF targets satellite cell activation and myocyte proliferation. Complementary pathways for comprehensive tissue repair post-injury or intensive training. BPC-157's systemic stability and oral bioavailability contrast with PEG-MGF's localized IGF-1R signaling.

PEG-MGF: 100–200 mcg SQ post-training
BPC-157: 250–500 mcg SQ or oral, twice daily
Duration: 4–6 weeks (injury-dependent)
Primary benefit: Accelerated muscle and connective tissue repair, enhanced recovery

+ TB-500

Strong

View TB-500 →

TB-500 (Thymosin Beta-4 fragment) upregulates actin polymerization, cell migration, and anti-inflammatory pathways, while PEG-MGF drives satellite cell proliferation via IGF-1R/mTOR. Synergistic for muscle regeneration: TB-500 mobilizes progenitor cells, PEG-MGF stimulates their differentiation into myocytes. Both have overlapping but distinct repair cascades.

PEG-MGF: 100–200 mcg SQ post-training
TB-500: 2–5 mg SQ, 2× per week (loading), then weekly
Timing: Stagger injections by 6–12 hours
Primary benefit: Maximal satellite cell recruitment and myogenic differentiation, injury repair

Survodutide

— no documented stacks